LLY / Pran, page-8

Funny that Prana just in the past year or two (exact date?) after no changes in the structure of the PBT2 compound to announce that PBT2 is effective not only for amyloid but now "works" on tau also. That coincided with the recent increased attention to tau. IMO that does not justify your "correction".

Many were awaiting Lilly's announcement of sola's third attempt at clinical trial results to also verify the beta amyloid theory in December at CTAD. Instead they announced this a.m. and resulted in a temporary drop in most beta amyloid related companies, a fact that you can't "correct". \

The IBB fell but that wouldn't matter to Prana since it does not qualify for membership in that higher-tier biotech group. Prana has not announced that they will attend CTAD. That's probably a wise choice. Those HD posters have been expensive without results. No reason to think that Prana AD posters would matter.

Thank you for not "correcting" this: "PRAN's little spike up is already on the way down."